SMG vs AMGN vs GILD vs SPB vs ABBV

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus -5. 2% for Spectrum Brands Holdings, Inc. (SPB). Gilead Sciences, Inc. (GILD) offers the better valuation at 19. 4x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate The Scotts Miracle-Gro Company (SMG) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Gilead Sciences, Inc.

(GILD) is the cheapest at 19. 4x versus AbbVie Inc. at 85. 0x. On forward P/E, The Scotts Miracle-Gro Company is actually cheaper at 13. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Gilead Sciences, Inc. wins at 0. 12x versus Amgen Inc. 's 5. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +117. 0%, compared to -69. 3% for The Scotts Miracle-Gro Company (SMG). Over 10 years, the gap is even starker: ABBV returned +293. 8% versus SPB's +15. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus The Scotts Miracle-Gro Company's 1. 12β — meaning SMG is approximately 307% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Spectrum Brands Holdings, Inc. (SPB) carries a lower debt/equity ratio of 34% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus -5. 2% for Spectrum Brands Holdings, Inc. (SPB). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -5. 6% for Spectrum Brands Holdings, Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus 3. 6% for Spectrum Brands Holdings, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus 4. 4% for SPB. At the gross margin level — before operating expenses — GILD leads at 78. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Gilead Sciences, Inc. (GILD) is the more undervalued stock at a PEG of 0. 12x versus Amgen Inc. 's 5. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, The Scotts Miracle-Gro Company (SMG) trades at 13. 9x forward P/E versus 15. 5x for Spectrum Brands Holdings, Inc. — 1. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 27. 4% to $256. 69.

All stocks in this comparison pay dividends.

The Scotts Miracle-Gro Company (SMG) offers the highest yield at 4. 3%, versus 2. 3% for Spectrum Brands Holdings, Inc. (SPB).

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). Both have compounded well over 10 years (ABBV: +293. 8%, SMG: +33. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SMG (Basic Materials) and AMGN (Healthcare) and GILD (Healthcare) and SPB (Consumer Defensive) and ABBV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SMG is a small-cap income-oriented stock; AMGN is a mid-cap quality compounder stock; GILD is a mid-cap quality compounder stock; SPB is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.